Naxicap, Ouest Croissance exit Lilial to trade

Coloplast, founded in 1954 and headquartered in Humlebæk, develops, manufactures and markets medical devices and services related to ostomy, urology, continence and wound care. It is currently listed on the London stock exchange. The company generated revenues of approximately €2.08bn in the 2016/17 financial year. It has a workforce of around 11,000 employees.

Previous funding
In 2014, Naxicap (as lead investor) and Ouest Croissance backed Lilial. The total funding for the deal, structured as an LBO, was not disclosed.  CIC Ouest and BPA arranged debt funding to support the acquisition.

Company
Founded in 2003, Lilial provides next-day home delivery of medical products for patients with incontinence, colostomy or other stoma, and scarring. Lilial's activity includes liaising with prescribing medical staff in functional re-education centres, clinics and hospitals, and supporting patients when they return home. The company employs 80 staff and was expected to have sales of €33m in 2017, against €17.4m in 2013. Lilial is headquartered in Saint-Barthélemy-d'Anjou.

People
Naxicap Partners – Luc Bertholat, Cyriaque Viaud (managing directors).
Ouest Croissance – Henri Guillermit (CEO); Olivier Philippon (investment manager).
Groupe Lilial – Denis Marliac (founder, CEO).
Coloplast – Lars Rasmussen (CEO). 

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Exits
• France
• Healthcare
• France
• Naxicap
• Ouest Croissance